This was elegantly achieved by exploitation of either the Tie2 or the MMP-14 promoters as ‘tumor-selective’ switch in macrophages derived from genetically engineered and transplanted HSCs [36–40, 42]. The gene discussed is TEK; the disease is neoplasm.